US6914130B2
(en)
*
|
1998-06-17 |
2005-07-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20050159588A1
(en)
*
|
1999-06-02 |
2005-07-21 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
SI2857516T1
(sl)
|
2000-04-11 |
2017-09-29 |
Genentech, Inc. |
Multivalentna protitelesa in njihove uporabe
|
EP1434778A4
(de)
*
|
2001-05-31 |
2005-07-13 |
Medarex Inc |
Cytotoxine und prodrugs, linker und stabilisatoren dafür
|
EP2277542B1
(de)
|
2001-06-01 |
2014-04-16 |
Cornell Research Foundation Inc. |
Modifizierte Antikörper gegen prostata-spezifisches Membranantigen und ihre Verwendungen
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20030148408A1
(en)
|
2001-09-18 |
2003-08-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
KR100576674B1
(ko)
|
2001-06-20 |
2006-05-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
KR100801388B1
(ko)
|
2002-01-02 |
2008-02-05 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
AU2012244218C1
(en)
*
|
2002-05-02 |
2016-12-15 |
Wyeth Holdings Llc. |
Calicheamicin derivative-carrier conjugates
|
AU2015246156B2
(en)
*
|
2002-05-02 |
2017-06-29 |
Wyeth Holdings Llc. |
Calicheamicin derivative-carrier conjugates
|
BR122019027974B1
(pt)
|
2002-05-02 |
2022-06-14 |
Wyeth Holdings Corporation |
Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso
|
PT2263691E
(pt)
|
2002-07-15 |
2012-11-12 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
PL1641822T3
(pl)
|
2003-07-08 |
2013-10-31 |
Genentech Inc |
Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
TW200539855A
(en)
*
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
NZ550217A
(en)
*
|
2004-03-31 |
2009-11-27 |
Genentech Inc |
Humanized anti-TGF-beta antibodies
|
NZ550934A
(en)
*
|
2004-05-19 |
2010-05-28 |
Medarex Inc |
Chemical linkers and conjugates thereof
|
US7691962B2
(en)
*
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
WO2006019447A1
(en)
|
2004-07-15 |
2006-02-23 |
Xencor, Inc. |
Optimized fc variants
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
ES2532610T3
(es)
|
2004-07-26 |
2015-03-30 |
Genentech, Inc. |
Procedimientos y composiciones para modular la activación del factor de crecimiento de hepatocitos
|
US20060045877A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
PT2990422T
(pt)
|
2004-09-03 |
2018-10-18 |
Genentech Inc |
Antagonistas humanizados anti-beta7 e suas utilizações
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP2845865A1
(de)
|
2004-11-12 |
2015-03-11 |
Xencor Inc. |
FC-Varianten mit Veränderter Bindung zu FCRN
|
EP1841793B1
(de)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
KR20170134771A
(ko)
|
2005-01-21 |
2017-12-06 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
KR20070115967A
(ko)
*
|
2005-02-18 |
2007-12-06 |
메다렉스, 인코포레이티드 |
전립선 특이 막 항원(psma)에 대한 인간 모노클로날항체
|
KR101253576B1
(ko)
|
2005-02-23 |
2013-04-11 |
제넨테크, 인크. |
Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
EP2384767B1
(de)
|
2005-03-24 |
2016-03-09 |
Millennium Pharmaceuticals, Inc. |
OV064-bindende Antikörper und Verfahren zu deren Verwendung
|
AU2006235258A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes
|
WO2006110599A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cacna1e in cancer diagnosis, detection and treatment
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
US20070003559A1
(en)
*
|
2005-07-01 |
2007-01-04 |
Wyeth |
Methods of determining pharmacokinetics of targeted therapies
|
CA2652434A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized proteins that target ep-cam
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US8795674B2
(en)
|
2005-09-30 |
2014-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods and compositions for modulating immune tolerance
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
AU2006305842B2
(en)
|
2005-10-26 |
2011-11-03 |
E. R. Squibb & Sons, L.L.C. |
Methods and compounds for preparing CC-1065 analogs
|
EP2465870A1
(de)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
WO2007081608A2
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
ES2388932T3
(es)
*
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
US20070237764A1
(en)
*
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
BRPI0619476A2
(pt)
*
|
2005-12-05 |
2011-10-04 |
Wyeth Corp |
composições de interleucina-11 e métodos de uso
|
JP5358187B2
(ja)
|
2005-12-15 |
2013-12-04 |
ジェネンテック, インコーポレイテッド |
ポリユビキチンを標的とする方法と組成物
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
TW200806685A
(en)
|
2006-02-21 |
2008-02-01 |
Wyeth Corp |
Processes for the convergent synthesis of calicheamicin derivatives
|
EP2946786A1
(de)
|
2006-03-08 |
2015-11-25 |
Wake Forest University Health Sciences |
Lösliches monomeres Ephrin-A1
|
PA8718601A1
(es)
|
2006-03-10 |
2009-05-15 |
Wyeth Corp |
Anticuerpos anti-5t4 y sus usos
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
CA2647107A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
MX2008013121A
(es)
|
2006-04-13 |
2009-03-25 |
Novartis Vaccines & Diagnostic |
Metodo para tratar, diagnosticar o detectar cancer.
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
EP2446904B1
(de)
|
2006-05-30 |
2015-04-29 |
Genentech, Inc. |
Anti-CD22 Antikörper, Immunkonjugate sowie ihre Verwendungen
|
AU2007285976B2
(en)
|
2006-08-14 |
2011-08-18 |
Xencor, Inc |
Optimized antibodies that target CD19
|
ES2530438T3
(es)
|
2006-09-12 |
2015-03-02 |
Genentech Inc |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
|
ES2535637T3
(es)
|
2006-10-27 |
2015-05-13 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
EP2962697A1
(de)
|
2006-11-27 |
2016-01-06 |
diaDexus, Inc. |
Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
PE20081760A1
(es)
|
2007-02-09 |
2009-01-01 |
Genentech Inc |
Anticuerpos anti-robo4 y sus usos
|
CA2678514A1
(en)
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
EP2899541A1
(de)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
|
EP2474556A3
(de)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1-Inhibitoren zur Behandlung, Diagnose und Erkennung von Krebs
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
PE20090309A1
(es)
*
|
2007-06-04 |
2009-04-18 |
Wyeth Corp |
Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
RS52305B
(en)
|
2007-07-16 |
2012-12-31 |
Genentech Inc. |
ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
|
MY163473A
(en)
|
2007-09-26 |
2017-09-15 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
PT2220116E
(pt)
|
2007-11-12 |
2012-12-07 |
Theraclone Sciences Inc |
Composições e métodos para a terapia e o diagnóstico da gripe
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
EP2238169A1
(de)
*
|
2007-12-26 |
2010-10-13 |
Biotest AG |
Verfahren zur verminderung der zytotoxischen nebenwirkungen und zur erhöhung der wirksamkeit von immunkonjugaten
|
CA2710471C
(en)
*
|
2007-12-26 |
2018-06-05 |
Biotest Ag |
Immunoconjugates targeting cd138 and uses thereof
|
CN101945892B
(zh)
*
|
2007-12-26 |
2017-11-24 |
生物测试股份公司 |
用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
|
KR101626416B1
(ko)
*
|
2007-12-26 |
2016-06-01 |
바이오테스트 아게 |
Cd138 표적 물질 및 이의 용도
|
HUE024903T2
(en)
|
2007-12-26 |
2016-02-29 |
Xencor Inc |
FC variants with modified binding to FCRN
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
AU2009223688B2
(en)
*
|
2008-03-10 |
2014-12-11 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
BRPI0906261A2
(pt)
*
|
2008-03-31 |
2015-07-07 |
Genentech Inc |
"métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
|
KR101855381B1
(ko)
|
2008-04-09 |
2018-05-09 |
제넨테크, 인크. |
면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
|
BRPI0908665A2
(pt)
*
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
EP2318832B1
(de)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Glycan-arrays auf objektträgern mit ptfe-aluminiumbeschichtung und entsprechende verfahren
|
KR101712214B1
(ko)
|
2008-10-01 |
2017-03-03 |
제넨테크, 인크. |
항-노치2 항체 및 사용 방법
|
EP2376117A1
(de)
|
2008-12-17 |
2011-10-19 |
Genentech, Inc. |
Hepatitis-c-virus-kombinationstherapie
|
CN106986933A
(zh)
|
2009-02-11 |
2017-07-28 |
阿尔布梅迪克斯医疗公司 |
白蛋白变体和缀合物
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
AR075896A1
(es)
|
2009-03-20 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-her (factor de crecimiento epidermico)
|
JP6051048B2
(ja)
|
2009-03-25 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
新規な抗α5β1抗体及びその使用
|
HUE025726T2
(en)
|
2009-03-25 |
2016-04-28 |
Genentech Inc |
Anti-FGFR3 antibodies and their use
|
SG174992A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
KR20110138412A
(ko)
|
2009-04-16 |
2011-12-27 |
애보트 바이오테라퓨틱스 코포레이션 |
항-ΤΝF-α 항체 및 그의 용도
|
US9296785B2
(en)
|
2009-04-17 |
2016-03-29 |
Wake Forest University Health Sciences |
IL-13 receptor binding peptides
|
US8609101B2
(en)
*
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
TWI529247B
(zh)
|
2009-05-13 |
2016-04-11 |
建新公司 |
抗人類cd52免疫球蛋白
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
KR101763808B1
(ko)
|
2009-06-04 |
2017-08-16 |
노파르티스 아게 |
IgG 콘쥬게이션을 위한 자리의 확인 방법
|
JP5785941B2
(ja)
|
2009-06-17 |
2015-09-30 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗vegf抗体とその使用
|
MX2012001306A
(es)
|
2009-07-31 |
2012-02-28 |
Genentech Inc |
Inhibicion de matastasis de tumor.
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
CN104945509A
(zh)
|
2009-09-16 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
WO2011045396A2
(en)
|
2009-10-16 |
2011-04-21 |
Novartis Ag |
Biomarkers of tumor pharmacodynamic response
|
CN102791739B
(zh)
*
|
2009-10-19 |
2014-10-15 |
霍夫曼-拉罗奇有限公司 |
肝细胞生长因子激活剂的调控物
|
MX2012004647A
(es)
|
2009-10-22 |
2012-06-19 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso.
|
WO2011050194A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011059762A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
RU2607374C2
(ru)
|
2009-10-30 |
2017-01-10 |
Новозаймс Байофарма Дк А/С |
Варианты альбумина
|
AU2010314981B2
(en)
|
2009-11-05 |
2015-07-02 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
JP5856065B2
(ja)
|
2009-11-30 |
2016-02-09 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
BR112012013717B1
(pt)
|
2009-12-10 |
2020-01-28 |
Hoffmann La Roche |
anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
EP2513148B1
(de)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2-antikörper und ihre verwendung
|
RU2559542C2
(ru)
|
2009-12-23 |
2015-08-10 |
Дженентек, Инк. |
Антитела против bv8 и их применение
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
JP5988436B2
(ja)
|
2010-02-23 |
2016-09-07 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
CN102918060B
(zh)
|
2010-03-05 |
2016-04-06 |
霍夫曼-拉罗奇有限公司 |
抗人csf-1r抗体及其用途
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
KR20130079384A
(ko)
|
2010-05-03 |
2013-07-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP3299380A1
(de)
|
2010-05-25 |
2018-03-28 |
F. Hoffmann-La Roche AG |
Verfahren zur aufreinigung von polypeptiden
|
RU2613886C2
(ru)
|
2010-06-03 |
2017-03-21 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
|
CN114246952A
(zh)
|
2010-06-08 |
2022-03-29 |
基因泰克公司 |
半胱氨酸改造的抗体和偶联物
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
MX2013001302A
(es)
|
2010-08-03 |
2013-03-08 |
Hoffmann La Roche |
Biomarcadores de leucemia linfocitica (cll).
|
CA2807664A1
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのIL−1β及びIL−18に対する抗体
|
JP5841149B2
(ja)
|
2010-08-13 |
2016-01-13 |
ロシュ グリクアート アーゲー |
抗テネイシンca2抗体及び使用の方法
|
MA34519B1
(fr)
|
2010-08-13 |
2013-09-02 |
Roche Glycart Ag |
Anticorps anti-fap et procédés d'utilisation
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
|
WO2012030904A2
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
MX2013002084A
(es)
|
2010-08-31 |
2013-05-09 |
Genentech Inc |
Biomarcadores y metodos de tratamiento.
|
WO2012034039A2
(en)
|
2010-09-10 |
2012-03-15 |
Apexigen, Inc. |
Anti-il-1 beta antibodies and methods of use
|
AU2011312417B2
(en)
|
2010-09-29 |
2015-08-20 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
EP3828205A1
(de)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1-antikörper
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CA2815840A1
(en)
|
2010-11-10 |
2012-05-18 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
AR084342A1
(es)
|
2010-12-16 |
2013-05-08 |
Genentech Inc |
Diagnostico y tratamientos relacionados con la inhibicion de th2
|
UA113838C2
(xx)
|
2010-12-20 |
2017-03-27 |
|
Антитіло, яке зв'язує мезотелін, та імунокон'югат
|
EP2655419A1
(de)
|
2010-12-22 |
2013-10-30 |
F.Hoffmann-La Roche Ag |
Anti-pcsk9-antikörper und verwendungsverfahren
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012106587A1
(en)
|
2011-02-04 |
2012-08-09 |
Genentech, Inc. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
US20120213781A1
(en)
|
2011-02-11 |
2012-08-23 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
MX342810B
(es)
|
2011-03-03 |
2016-10-13 |
Apexigen Inc |
Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
|
AU2012225246B2
(en)
|
2011-03-10 |
2016-01-21 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
BR112013023576A2
(pt)
|
2011-03-15 |
2016-12-06 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
SG193554A1
(en)
|
2011-03-29 |
2013-11-29 |
Roche Glycart Ag |
Antibody fc variants
|
BR112013024717A2
(pt)
|
2011-04-07 |
2017-08-08 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
CN103635488B
(zh)
|
2011-04-29 |
2016-12-14 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
MY175338A
(en)
|
2011-05-16 |
2020-06-19 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
DK3415531T3
(da)
|
2011-05-27 |
2023-09-18 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17)-bindende proteiner
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
EP2742067A4
(de)
|
2011-08-12 |
2015-03-04 |
Omeros Corp |
Monoklonale fzd10-antikörper und verfahren zu ihrer verwendung
|
JP2014525412A
(ja)
|
2011-08-17 |
2014-09-29 |
ジェネンテック, インコーポレイテッド |
難治性腫瘍における血管新生の阻害
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
MX2014001799A
(es)
|
2011-08-23 |
2014-03-31 |
Roche Glycart Ag |
Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
JP2014533927A
(ja)
|
2011-09-15 |
2014-12-18 |
ジェネンテック, インコーポレイテッド |
分化を促進する方法
|
JP2014534949A
(ja)
|
2011-09-19 |
2014-12-25 |
ジェネンテック, インコーポレイテッド |
C−metアンタゴニストおよびb−rafアンタゴニストを含む組合せ処置
|
RU2014114119A
(ru)
|
2011-09-23 |
2015-10-27 |
Рош Гликарт Аг |
Биспецифические анти-egfr/анти igf-1r-антитела
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP2766028B1
(de)
|
2011-10-14 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Peptidinhibitoren von bace1
|
EA201490778A1
(ru)
|
2011-10-14 |
2014-09-30 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
PE20142312A1
(es)
|
2011-10-28 |
2015-01-25 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma
|
PL2773438T5
(pl)
|
2011-11-02 |
2022-01-17 |
F.Hoffmann-La Roche Ag |
Chromatografia przeciążenia i elucji
|
BR112014010774A2
(pt)
|
2011-11-02 |
2017-06-13 |
Apexigen Inc |
anticorpos anti-kdr e métodos de uso
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
JP2014533700A
(ja)
|
2011-11-21 |
2014-12-15 |
ジェネンテック, インコーポレイテッド |
抗c−MET抗体の精製
|
CA2858133A1
(en)
|
2011-12-08 |
2013-06-13 |
Biotest Ag |
Uses of immunoconjugates targeting cd138
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP3663314A1
(de)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanisierte antikörper mit ultralangem cdr3s
|
BR112014017518A2
(pt)
|
2012-01-18 |
2018-09-04 |
Genentech Inc |
anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
|
CN104168920A
(zh)
|
2012-01-18 |
2014-11-26 |
霍夫曼-拉罗奇有限公司 |
使用fgf19调控剂的方法
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
US20130209473A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
JP6152120B2
(ja)
|
2012-02-15 |
2017-06-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体に基づくアフィニティークロマトグラフィー
|
CA2861592A1
(en)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
EP2844300B1
(de)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17-antikörper und immunkonjugate
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
CA2871386A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
CN104411725B
(zh)
|
2012-07-04 |
2018-09-28 |
弗·哈夫曼-拉罗切有限公司 |
抗生物素抗体及使用方法
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
RU2017128512A
(ru)
|
2012-07-04 |
2019-02-15 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к теофиллину и способы их применения
|
CN104428315B
(zh)
|
2012-07-13 |
2017-09-29 |
罗氏格黎卡特股份公司 |
双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
SG11201501286PA
(en)
|
2012-08-23 |
2015-05-28 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
PL2897978T3
(pl)
|
2012-09-19 |
2017-08-31 |
Abbvie Biotherapeutics Inc. |
Sposoby identyfikacji przeciwciał o obniżonej immunogenności
|
EP2904016B1
(de)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-freie antikörper mit zwei fab-fragmenten sowie verwendungsverfahren dafür
|
CA2888763A1
(en)
|
2012-10-30 |
2014-05-08 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
JP6694712B2
(ja)
|
2012-11-01 |
2020-05-20 |
マックス−デルブルック−セントラム フアー モレキュラーレ メデジン |
Cd269(bcma)に対する抗体
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
WO2014072481A1
(en)
|
2012-11-08 |
2014-05-15 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
WO2014078268A2
(en)
|
2012-11-13 |
2014-05-22 |
Genentech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
EP2920586A4
(de)
|
2012-11-15 |
2017-01-04 |
F. Hoffmann-La Roche SA |
Durch ionenstärke vermittelte ph-gradienten-ionenaustausch-chromatografie
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
EP3620473A1
(de)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Neuartige heterodimere proteine
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
WO2014131715A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP3299391B1
(de)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
WO2014151866A1
(en)
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP2970452A2
(de)
|
2013-03-15 |
2016-01-20 |
AC Immune S.A. |
Anti-tau-antikörper und verfahren zur verwendung
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
BR112015023203A8
(pt)
|
2013-03-15 |
2018-01-23 |
Constellation Pharmaceuticals Inc |
métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
EP2970488A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25-antikörper und deren verwendungen
|
EP2970471A2
(de)
|
2013-03-15 |
2016-01-20 |
F. Hoffmann-La Roche AG |
Anti-crth2-antikörper und deren verwendung
|
CA2902739C
(en)
|
2013-03-15 |
2022-11-22 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
KR102158924B1
(ko)
|
2013-03-15 |
2020-09-22 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
CA2904527A1
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Biotechnology Ltd. |
Anti-cd25 antibodies and their uses
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
PL2992010T3
(pl)
|
2013-04-29 |
2021-08-23 |
F.Hoffmann-La Roche Ag |
Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
|
EP2992329A1
(de)
|
2013-05-03 |
2016-03-09 |
Eleven Biotherapeutics, Inc. |
An fcrn bindende albuminvarianten
|
MA38632B1
(fr)
|
2013-05-20 |
2019-10-31 |
Genentech Inc |
Anticorps anti-récepteur de transferrine et procédés d'utilisation
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
CA2918052A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
US20150093800A1
(en)
|
2013-09-05 |
2015-04-02 |
Genentech, Inc. |
Method for chromatography reuse
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
BR112016004450A2
(pt)
|
2013-09-17 |
2017-10-17 |
Genentech Inc |
métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
|
CR20160156A
(es)
|
2013-10-11 |
2016-11-01 |
Oxford Biotherapeutics Ltd |
Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
EP3065780A1
(de)
|
2013-11-04 |
2016-09-14 |
Pfizer Inc. |
Anti-efna4-antikörper-arzneimittelkonjugate
|
CA2931340A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
PE20161394A1
(es)
|
2013-12-16 |
2017-01-06 |
Genentech Inc |
Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
CN111228509A
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
|
WO2015101587A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
EP3089759B1
(de)
|
2014-01-03 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Kovalent verknüpfte polypeptidtoxin-antikörperkonjugate
|
EP3094352B1
(de)
|
2014-01-16 |
2020-09-23 |
Academia Sinica |
Zusammensetzungen und verfahren zur behandlung und zum nachweis von krebs
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
ES2694857T3
(es)
|
2014-02-04 |
2018-12-27 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
EP3825332A1
(de)
|
2014-02-12 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Anti-jagged1-antikörper und verfahren zur verwendung
|
CA2937556A1
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
UY36041A
(es)
|
2014-03-21 |
2015-09-30 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
ME03666B
(de)
|
2014-03-28 |
2020-10-20 |
Xencor Inc |
Bispezifische, an cd38 und cd3 bindende antikörper
|
HUE046767T2
(hu)
|
2014-03-31 |
2020-03-30 |
Hoffmann La Roche |
Anti-OX40 antitestek és alkalmazási eljárások
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
CA2943299A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Bispecific her2 antibodies
|
EP3140392B1
(de)
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Herstellung von heteromultimeren proteinen mittels säugerzellen
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
CA2950577A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
KR20220151036A
(ko)
|
2014-05-27 |
2022-11-11 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
KR102494193B1
(ko)
|
2014-05-28 |
2023-01-31 |
아카데미아 시니카 |
항-tnf-알파 글리코항체 및 이의 용도
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
CN106687476B
(zh)
|
2014-06-26 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
抗brdu抗体及使用方法
|
US9914774B2
(en)
|
2014-07-11 |
2018-03-13 |
Genentech, Inc. |
Notch pathway inhibition
|
WO2016014984A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
EP3186284B1
(de)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Bedingt aktive chimäre antigenrezeptoren für modifizierte t-zellen
|
EP3191500A4
(de)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
|
EA201790545A1
(ru)
|
2014-09-12 |
2017-07-31 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против her2
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
CN106804108B
(zh)
|
2014-09-12 |
2021-08-10 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
BR112017003236A2
(pt)
|
2014-09-12 |
2017-11-28 |
Genentech Inc |
anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
|
EP3262071B8
(de)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von anti-cd79b-immunkonjugaten
|
BR112017006602A2
(pt)
|
2014-10-01 |
2017-12-19 |
Medimmune Llc |
método de conjugação de um polipeptídeo
|
EP3207057A2
(de)
|
2014-10-16 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Anti-alpha-synuklein-antikörper und verfahren zur verwendung
|
WO2016070062A2
(en)
|
2014-10-31 |
2016-05-06 |
Genentech, Inc. |
Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
EP3221364B1
(de)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
|
EP3221362B1
(de)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
|
CN107250158B
(zh)
|
2014-11-19 |
2022-03-25 |
基因泰克公司 |
抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
|
EP3223845B1
(de)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Cheterodimere antikörper zur bindung von cd3 und cd20
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
KR20170084327A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 cd38에 결합하는 이형이량체 항체
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
AR102918A1
(es)
|
2014-12-05 |
2017-04-05 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
RU2017120039A
(ru)
|
2014-12-10 |
2019-01-10 |
Дженентек, Инк. |
Антитела к рецепторам гематоэнцефалического барьера и способы их применения
|
WO2016098356A1
(en)
|
2014-12-19 |
2016-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2973964A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
EP3247723A1
(de)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Kombination von zwei oder mehr anti-c5-antikörpern und verfahren zur verwendung
|
EP3248005B1
(de)
|
2015-01-24 |
2020-12-09 |
Academia Sinica |
Neuartige glycankonjugate und verfahren zur verwendung davon
|
KR102630294B1
(ko)
|
2015-01-24 |
2024-01-26 |
아카데미아 시니카 |
암 마커 및 이를 사용하는 방법
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
EP3816179A3
(de)
|
2015-02-05 |
2021-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-region-variante, mit einer modifizierten fcrn-bindungsdomäne
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
JP6952605B2
(ja)
|
2015-04-24 |
2021-10-20 |
ジェネンテック, インコーポレイテッド |
多特異性抗原結合タンパク質
|
JP2018520642A
(ja)
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
EP4238994A3
(de)
|
2015-05-11 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
LT3294770T
(lt)
|
2015-05-12 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Vėžio gydymo ir diagnostikos būdai
|
AU2016267691B2
(en)
|
2015-05-28 |
2022-06-16 |
Genentech, Inc. |
Cell-based assay for detecting anti-CD3 homodimers
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
MX2017014736A
(es)
|
2015-05-29 |
2018-03-23 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
US20160355597A1
(en)
|
2015-06-08 |
2016-12-08 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
CA2986928A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
PE20221008A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN107921128B
(zh)
|
2015-08-05 |
2022-04-26 |
詹森生物科技公司 |
抗cd154抗体及其使用方法
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3337816B1
(de)
|
2015-08-20 |
2024-02-14 |
Albumedix Ltd |
Albumin-varianten und -konjugate
|
MA42924A
(fr)
|
2015-09-23 |
2018-08-01 |
Hoffmann La Roche |
Variants optimisés d'anticorps anti-vegf
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
AU2016325610B2
(en)
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
AU2016329057A1
(en)
|
2015-09-30 |
2018-04-12 |
Janssen Biotech, Inc. |
Antagonistic antibodies specifically binding human CD40 and methods of use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
EP3356404B1
(de)
|
2015-10-02 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-pd1-antikörper und verfahren zur verwendung
|
PE20181004A1
(es)
|
2015-10-02 |
2018-06-26 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
CR20180161A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Anticuerpos biespecíficos para pd1 y tim3
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
*
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
JP6920292B2
(ja)
|
2015-10-30 |
2021-08-18 |
ジェネンテック, インコーポレイテッド |
ヒンジが修飾された抗体断片及び作製方法
|
US10894830B2
(en)
|
2015-11-03 |
2021-01-19 |
Janssen Biotech, Inc. |
Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Cd3及びpsmaに結合するヘテロ二量体抗体
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
BR112018003984A2
(pt)
|
2015-12-09 |
2018-09-25 |
Hoffmann La Roche |
anticorpos
|
MX2018007144A
(es)
|
2015-12-18 |
2018-11-29 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso.
|
CN109073635A
(zh)
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
AU2017212484C1
(en)
|
2016-01-27 |
2020-11-05 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
EP3865511A1
(de)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3-antikörper und verfahren zur verwendung
|
MX2018012433A
(es)
|
2016-04-15 |
2019-03-01 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
KR20230162730A
(ko)
|
2016-04-15 |
2023-11-28 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
KR102523682B1
(ko)
|
2016-05-02 |
2023-04-19 |
에프. 호프만-라 로슈 아게 |
콘톨스바디 - 단쇄 표적 결합제
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2018220099A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
CN109562169A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
EP4371570A2
(de)
|
2016-06-08 |
2024-05-22 |
Xencor, Inc. |
Behandlung von erkrankungen im zusammenhang mit igg4 mit anti-cd19-antikörpern mit kreuzbindung an cd32b
|
CN116284404A
(zh)
|
2016-06-08 |
2023-06-23 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
WO2017214339A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
AU2017277916A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
US10316088B2
(en)
|
2016-06-28 |
2019-06-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
KR20230107408A
(ko)
|
2016-07-29 |
2023-07-14 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
US11066479B2
(en)
|
2016-08-02 |
2021-07-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
JP7286536B2
(ja)
|
2016-08-15 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非イオン性サーファクタント及びポリペプチドを含む組成物中の非イオン性サーファクタントを定量するためのクロマトグラフィー法
|
CN109963868B
(zh)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
抗体、结合片段及使用方法
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
EP3523451A1
(de)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutische und diagnostische verfahren für krebs
|
KR102562519B1
(ko)
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
US20210308277A1
(en)
|
2016-11-14 |
2021-10-07 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
|
EP3541843A1
(de)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosierung zur behandlung mit anti-cd20/anti-cd3-bispezifischen antikörpern
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
AU2017382883A1
(en)
|
2016-12-21 |
2019-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
CN116715775A
(zh)
|
2017-02-10 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AU2018268970A1
(en)
|
2017-05-19 |
2019-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
EP3699590A4
(de)
|
2017-10-20 |
2021-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur messung der internalisierung eines moleküls in eine zelle
|
AU2018358883A1
(en)
|
2017-10-30 |
2020-04-23 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
KR102559706B1
(ko)
|
2017-11-01 |
2023-07-25 |
에프. 호프만-라 로슈 아게 |
Trifab-콘톨스바디
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
EP3732195A4
(de)
|
2017-12-28 |
2022-02-09 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
CA3089287A1
(en)
|
2018-02-08 |
2019-08-15 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
WO2019177543A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
JP2021523741A
(ja)
|
2018-05-14 |
2021-09-09 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なインターロイキン12ポリペプチド及びその使用方法
|
CN113840832A
(zh)
|
2018-05-14 |
2021-12-24 |
狼人治疗公司 |
可活化白介素-2多肽及其使用方法
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
JOP20200343A1
(ar)
|
2018-07-02 |
2020-12-31 |
Xencor Inc |
بروتين ربط مولد ضد مضاد لـ steap1
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
WO2020033430A1
(en)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
KR102259473B1
(ko)
|
2018-08-10 |
2021-06-02 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP3856764A4
(de)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
Maskierte cytokin-polypeptide
|
CA3115096A1
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
EP3867646A1
(de)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
WO2020127968A1
(en)
|
2018-12-20 |
2020-06-25 |
Marino Stephen F |
Protein-drug conjugate comprising a monomeric form of proteinase 3
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
US20220064301A1
(en)
|
2018-12-26 |
2022-03-03 |
Xilio Development, Inc. |
Anti-ctla4 antibodies and methods of use thereof
|
CN113490510A
(zh)
|
2019-01-08 |
2021-10-08 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
|
AU2020211974A1
(en)
|
2019-01-22 |
2021-08-05 |
Genentech, Inc. |
Immunoglobulin a antibodies and methods of production and use
|
AU2020212534A1
(en)
|
2019-01-22 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
EP3915581A4
(de)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Neuartige krebsantigene und antikörper dieser antigene
|
WO2020160050A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
US11472890B2
(en)
|
2019-03-01 |
2022-10-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
AU2020236015A1
(en)
|
2019-03-14 |
2021-09-09 |
Genentech, Inc. |
Treatment of cancer with HER2XCD3 bispecific antibodies in combination with anti-HER2 MAB
|
JP2022528804A
(ja)
|
2019-04-18 |
2022-06-15 |
ジェネンテック, インコーポレイテッド |
抗体力価試験
|
EP3956022A1
(de)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von prostatakrebs mit einem anti-psma-cd3-antikörper
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
TW202108178A
(zh)
|
2019-05-14 |
2021-03-01 |
美商建南德克公司 |
使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
MX2021013441A
(es)
|
2019-05-15 |
2021-12-10 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigenos, composicion farmaceutica y metodo.
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
BR112021023173A2
(pt)
|
2019-07-10 |
2022-01-04 |
Chugai Pharmaceutical Co Ltd |
Moléculas de ligação à claudin-6 e usos das mesmas
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
AU2020365836A1
(en)
|
2019-10-18 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma
|
US20220380471A1
(en)
|
2019-10-22 |
2022-12-01 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7-h3 (cd276) for treating multiple solid tumors
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
EP4069742A1
(de)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypische antikörper gegen gprc5d-gerichtete bindungsdomänen und verwandte zusammensetzungen und verfahren
|
KR20220122653A
(ko)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Bcma-표적 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
|
CA3161573A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
IL294226A
(en)
|
2019-12-27 |
2022-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibodies and their use
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
JP2023517345A
(ja)
|
2020-03-13 |
2023-04-25 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン-33抗体及びその使用
|
TW202144408A
(zh)
|
2020-03-19 |
2021-12-01 |
美商建南德克公司 |
同功型選擇性抗-TGF-β抗體及其使用方法
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2021217051A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
CA3188000A1
(en)
|
2020-07-13 |
2022-01-20 |
Genentech, Inc. |
Cell-based methods for predicting polypeptide immunogenicity
|
WO2022025184A1
(ja)
|
2020-07-29 |
2022-02-03 |
中外製薬株式会社 |
非放射性物質で標識した薬剤の薬物動態を測定する方法
|
EP4192868A1
(de)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Antiidiotypische antikörper gegen ror1-gerichtete bindungsdomänen und zugehörige zusammensetzungen und verfahren
|
BR112023002123A2
(pt)
|
2020-08-07 |
2023-03-07 |
Genentech Inc |
Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
|
JP2023537683A
(ja)
|
2020-08-07 |
2023-09-05 |
ジェネンテック, インコーポレイテッド |
ポリペプチド免疫原性を予測するためのt細胞ベースの方法
|
EP4225443A1
(de)
|
2020-10-05 |
2023-08-16 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-fcrh5/anti-cd3-antikörpern
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
US20240000846A1
(en)
|
2020-10-27 |
2024-01-04 |
Vor Biopharma Inc. |
Compositions and methods for treating hematopoietic malignancy
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
WO2022098648A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
AU2022214491A1
(en)
|
2021-01-28 |
2023-09-14 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
EP4301467A1
(de)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Kombination von ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
|
JP2024508488A
(ja)
|
2021-03-01 |
2024-02-27 |
エクシリオ デベロップメント, インコーポレイテッド |
がんを治療するためのマスクされたctla4及びpd1/pd-l1抗体の組み合わせ
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
CN117396232A
(zh)
|
2021-05-12 |
2024-01-12 |
基因泰克公司 |
使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
|
WO2022244838A1
(ja)
|
2021-05-19 |
2022-11-24 |
中外製薬株式会社 |
分子のin vivo薬物動態を予測する方法
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
EP4352099A1
(de)
|
2021-06-09 |
2024-04-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Gegen pd-l1 gerichtete cross-species-einzeldomänenantikörper zur behandlung von soliden tumoren
|
AR126236A1
(es)
|
2021-06-25 |
2023-10-04 |
Chugai Pharmaceutical Co Ltd |
Uso del anticuerpo anti-ctla-4
|
TW202317627A
(zh)
|
2021-06-25 |
2023-05-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
TW202337499A
(zh)
|
2021-08-07 |
2023-10-01 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
US11987641B2
(en)
|
2021-08-27 |
2024-05-21 |
Janssen Biotech, Inc. |
Anti-PSMA antibodies and uses thereof
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|
TW202337904A
(zh)
|
2022-01-07 |
2023-10-01 |
美商壯生和壯生企業創新公司 |
IL-1β結合蛋白之材料及方法
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
US20230406930A1
(en)
|
2022-04-13 |
2023-12-21 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023215293A1
(en)
|
2022-05-02 |
2023-11-09 |
Athanor Biosciences, Inc. |
Cancer eradicating – bio-nanoparticles (ce-bnp)
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024073751A1
(en)
|
2022-09-29 |
2024-04-04 |
Vor Biopharma Inc. |
Methods and compositions for gene modification and enrichment
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|